6 results on '"Tsai, Wen-Sy"'
Search Results
2. Comparison of clinical outcomes of stoma reversal during versus after chemotherapy for rectal cancer patients
- Author
-
Tsai, Kun-Yu, You, Jeng-Fu, Huang, Shu-Huan, Tsai, Tzong-yun, Hsieh, Pao-Shiu, Lai, Cheng-Chou, Tsai, Wen-Sy, and Hung, Hsin-Yuan
- Published
- 2023
- Full Text
- View/download PDF
3. Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
- Author
-
Chiang, Ting-Yu, Hsu, Hung-Chih, Chern, Yih-Jong, Liao, Chun-Kai, Hsu, Yu-Jen, Tsai, Wen-Sy, Hsieh, Pao-Shiu, Lin, Yu-Fen, Lee, Hsiu-Lan, and You, Jeng-Fu
- Subjects
ACNE ,EPIDERMAL growth factor receptors ,AGE distribution ,METASTASIS ,RETROSPECTIVE studies ,CANCER relapse ,COLORECTAL cancer ,CANCER patients ,SEX distribution ,DRUG eruptions ,PROGRESSION-free survival ,BODY mass index ,OVERALL survival ,TUMOR grading - Abstract
Simple Summary: Targeted therapy and chemotherapy are the mainstays of treatment to improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and BRAF genes are normal, a molecular target treatment with an anti-EGFR antagonist is prescribed. Anti-EGFR antagonists induce skin responses in 50–70% of patients. There is an ongoing debate about whether the severe skin reactions brought on by anti-EGFR antagonists are associated with overall survival (OS) and progression-free survival (PFS). mCRC patients who received anti-EGFR therapy between October 2017 and October 2018 were retrospectively evaluated. Treatment with an anti-EGFR medication in the first-line setting was significantly associated with OS and PFS. In grades 1 and 2, there was no difference in the incidence of acne between males and females, although in grades 3 and 4, males were at a higher risk than females. In this study, skin toxicity did not predict the effectiveness of the anti-EGFR medication. The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50–70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Preoperative Cancer Inflammation Prognostic Index as a Superior Predictor of Short- and Long-Term Outcomes in Patients with Stage I–III Colorectal Cancer after Curative Surgery.
- Author
-
You, Jeng-Fu, Hsu, Yu-Jen, Chern, Yih-Jong, Cheng, Ching-Chung, Jong, Bor-Kang, Liao, Chun-Kai, Hsieh, Pao-Shiu, Hsu, Hung-Chih, and Tsai, Wen-Sy
- Subjects
PREOPERATIVE care ,STATISTICS ,MULTIVARIATE analysis ,INFLAMMATION ,SURGERY ,PATIENTS ,DISEASE incidence ,CANCER relapse ,RETROSPECTIVE studies ,COLORECTAL cancer ,NEUTROPHIL lymphocyte ratio ,TREATMENT effectiveness ,CANCER patients ,COMPARATIVE studies ,DESCRIPTIVE statistics ,PREDICTION models ,TUMOR markers ,TUMOR antigens ,SENSITIVITY & specificity (Statistics) ,PROGRESSION-free survival ,EVALUATION - Abstract
Simple Summary: Inflammatory reactions may lead to systemic inflammation and cancer growth. Some inflammatory indicators are effective predictors of colorectal cancer in ordinary clinical practice. The objective of this study is to evaluate the utility of a novel cancer-inflammation prognostic index (CIPI) marker derived from multiplying carcinoembryonic antigen by the neutrophil-to-lymphocyte ratio value obtained for non-metastatic colorectal cancer. Patients who underwent radical resection for stage I to stage III primary colorectal cancer between January 1995 and December 2018 were included in this study for further investigation. The group with a high CIPI had considerably lower relapse-free survival and overall survival rates, as well as a greater incidence of recurrence. Both univariate and multivariate analyses found that a high CIPI was an independent prognostic factor for survival analysis. This research is the first to demonstrate that CIPI is an independent factor that can be used to predict the outcome of colorectal cancer. Inflammatory reactions play a crucial role in cancer progression and may contribute to systemic inflammation. In routine clinical practice, some inflammatory biomarkers can be utilized as valuable predictors for colorectal cancer (CRC). This study aims to determine the usefulness of a novel cancer-inflammation prognostic index (CIPI) marker derived from calculating carcinoembryonic antigen (CEA) multiplied by the neutrophil-to-lymphocyte ratio (NLR) values established for non-metastatic CRCs. Between January 1995 and December 2018, 12,092 patients were diagnosed with stage I to III primary CRC and had radical resection—they were all included in this study for further investigation. There were 5996 (49.6%) patients in the low-CIPI group and 6096 (50.4%) patients in the high-CIPI group according to the cutoff value of 8. For long-term outcomes, the high-CIPI group had a significantly higher incidence of recurrence (30.6% vs. 16.0%, p < 0.001) and worse relapse-free survival (RFS) and overall survival (OS) rates (p < 0.001). High CIPI was an independent prognostic factor for RFS and OS in univariate and multivariate analyses. This research is the first to document the independent significance of CIPI as a prognostic factor for CRC. To ensure that it works, this CIPI needs to be tested on more CRC prediction models. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. The impact of kidney function on colorectal cancer patients with localized and regional diseases: An observational study from Taiwan.
- Author
-
Sum-Fu Chiang, Jinn-Shiun Chen, Reiping Tang, Chien-Yuh Yeh, Pao-Shiu Hsieh, Wen-Sy Tsai, Jeng-Fu You, Hsin-Yuan Hung, Cheng-Chou Lai, Jr-Rung Lin, Jy-Ming Chiang, Chiang, Sum-Fu, Chen, Jinn-Shiun, Tang, Reiping, Yeh, Chien-Yuh, Hsieh, Pao-Shiu, Tsai, Wen-Sy, You, Jeng-Fu, Hung, Hsin-Yuan, and Lai, Cheng-Chou
- Subjects
COLORECTAL cancer ,CANCER patients ,PROPORTIONAL hazards models ,RECEIVER operating characteristic curves - Abstract
Background: Impaired kidney function is associated with different diseases. However, its impact on colorectal cancer has not been clarified. In order to understand the effect of preoperative kidney function on the outcome of patients with cancer, we analyzed colorectal cancer patients with localized or regional diseases.Materials and Methods: In total, 3731 stage I to III colorectal cancer (CRC) patients were analyzed in Chang Gung Memorial Hospital. Modification of Diet in Renal Disease (MDRD) formula was used for estimated glomerular filtration rate (eGFR). Receiver operating characteristic (ROC) analysis for kidney function cut-off value; Chi-square method, independent t test, or analysis of variance (ANOVA) method for clinicopathological factors; Kaplan-Meier method for disease-free survival (DFS); Cox proportional hazard model for multivariate analysis.Results: Among colon cancer patients, low eGFR (MDRD <70) was associated with more male patients, T2 stage, patients without adjuvant chemotherapy, and patients with elevated creatinine level. Low eGFR is a significant risk factor only for stage III colon cancer (hazard ratio 1.70, 95% CI: 1.28-2.26; P < 0.001). Furthermore, postoperative adjuvant chemotherapy did not significantly increase 5-year DFS for both high and low eGFR groups in stage II patients (5 yrs DFS, 94.8% vs. 84.1%, P = 0.098 for high eGFR subgroup; and 75.0% vs. 75.8%, P = 0.379 for low eGFR subgroup). However, significant improvement of 5-yrs DFS after chemotherapy was found in low eGFR stage III colon cancer patients (64.7% vs. 39.4%, P < 0.001 for low eGFR subgroup). In contrast, no significant DFS difference was caused by chemotherapy for high eGFR stage III subgroup (70.5% vs. 63.9%, P = 0.110).Conclusions: Although low eGFR is an independent risk factor for stage III colon cancer. However, the adjuvant chemotherapy impacts on stage III colon cancer patients differently according to eGFR status. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.
- Author
-
Hsu, Hung-Chih, Lapke, Nina, Chen, Shu-Jen, Lu, Yen-Jung, Jhou, Ren-Shiang, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Hsieh, Jason Chia-Hsun, Yang, Tsai-Sheng, Thiam, Tan Kien, and You, Jeng-Fu
- Subjects
BEVACIZUMAB ,BIOMARKERS ,CANCER chemotherapy ,CELLULAR signal transduction ,CONFIDENCE intervals ,COLON tumors ,DRUG resistance in cancer cells ,LONGITUDINAL method ,METASTASIS ,MULTIVARIATE analysis ,GENETIC mutation ,PHOSPHATASES ,SURVIVAL ,RECTUM tumors ,RELATIVE medical risk ,DISEASE progression ,SEQUENCE analysis ,ODDS ratio ,DIAGNOSIS ,PROGNOSIS - Abstract
Background: Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response. Methods: Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were analyzed by next-generation sequencing of all coding exons of more than 400 genes. Single gene and signaling pathway analyses were performed to correlate genomic data with response. Results: Among the genes most frequently mutated in our cohort, only mutations in PTPRT, a phosphatase involved in JAK/STAT signaling, were associated with response status, with deleterious mutations being enriched in non-responders. Pathway analysis revealed that deleterious mutations in genes of the JAK/STAT pathway, namely in PTPRT and the related gene PTPRD, correlated with resistance. Mutations in RTK/PI3K/RAS, Wnt and TGFβ pathways did not associate with response. Lack of response was observed in all patients with deleterious mutations or copy number loss of PTPRT/PTPRD (n = 10), compared to only 30.8% (n = 8) of patients without such alterations (relative risk, 3.25; 95% CI, 1.83–5.79, p = 0.0003). Similarly, PTPRT/PTPRD deleterious alterations were associated with shorter progression-free survival, an association that was retained in multivariate analysis (HR, 3.33; 95% CI, 1.47–7.54; p = 0.0038). Conclusion: Deleterious alterations in PTPRT/PTPRD are potential biomarkers for bevacizumab resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.